LOGIN  |  REGISTER
Chimerix
Chimerix

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

July 30, 2025 | Last Trade: US$7.49 0.35 -4.46

GAITHERSBURG, Md., July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, August 6, 2025. Details of the event and replay are as follows:

Conference call details:

 

Date:

August 6, 2025

Time:

8:30 a.m. U.S. ET

URL to register phone:

Register Here

Dial-in number:

(888) 880-3330 (Domestic) or

 

(+1) (646) 357-8766 (International)

Webcast:

ir.novavax.com/events

  • Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
  • Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.

Replay details:

 

Date:

Available starting at 11:30 a.m. U.S. ET, August 6, 2025, until 11:59 p.m. U.S. ET, August 13, 2025

Dial-in number:

(800) 770-2030 (Domestic) or

 

(+1) (609) 800-9909 (International)

Passcode:

3041984#

Webcast:

ir.novavax.com/events, until September 5, 2025

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.

Contacts: 

Investors
Luis Sanay, CFA
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media
Giovanna Chandler
844-264-8571
This email address is being protected from spambots. You need JavaScript enabled to view it.

 
Terns Pharmaceuticals

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page